Clinical Trial Listing

Below are the clinical trials we are currently offering at Banner MD Anderson Cancer Center. Please continue to check back as we will continue to add additional trials to this list.

If you are interested in participating in any of these trials, please call (480) 256-6444.

For more information about these trials please visit ClinicalTrials.gov.

Brain Cancer

Breast Cancer

A Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, hormone Receptor-Positive and HER2/neu Negative Breast Cancer (NCT 01674140)
Principal Investigator: Dr. Mary Cianfrocca

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer (NCT03155997)
Principal Investigator: Dr. Lida Mina

A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy (NCT02032823)
Principal Investigator: Dr. Shakeela Bahadur

A Phase II, Multicenter, Open-label, Two-cohort, Non-comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After CDK 4/6 Inhibitor Treatment (NCT03056755)
Principal Investigator: Dr. Shakeela Bahadur

A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-Related Genes (Including BRCA1/2) (VIOLETTE) (NCT03330847)
Principal Investigator: Dr. Shakeela Bahadur

Effect of Preoperative Breast MRI on Surgical Outcomes, Cost and Quality of Life of Women with Breast Cancer (NCT01805076) 
Principal Investigator: Dr. Julie Billar 

CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2: A Prospective, Multicenter, Observational Study Examining the Clinical Utility of CANscriptTM in Routine Clinical Practice (NCT03253575)
Principal Investigator: Dr. Madappa Kundranda

A Phase 2, Non-randomized, Open Label, Single Arm, Multi-center Study Of Talazoparib For Neoadjuvant Treatment Of Germline Brca1/2 Mutation Patients With Early Triple-negative Breast Cancer (NCT03499353)
Principal Investigator: Dr. Lida Mina

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NCT01872975)
Principal Investigator: Dr. Emily Grade

Gastrointestinal Cancer (Pancreatic, Colorectal, Gastric, Liver, Biliary and Neuroendocrine Cancers)

Biliary Cancer

Phase 1/2 Study of TAS-120 in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations (NCT02052778)
Principal Investigator: Dr. Madappa Kundranda 

Colorectal Cancer

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES) (NCT01349881)
Principal Investigator: Dr. Tomislav Dragovich 

CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2: A Prospective, Multicenter, Observational Study Examining the Clinical Utility of CANscriptTM in Routine Clinical Practice (NCT03253575)
Principal Investigator: Dr. Madappa Kundranda

A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer (NCT02921256)
Principal Investigator: Dr.Gary Walker

Phase 1, Two-part (Dose Escalation, Dose Expansion), Multicenter, Non-randomized, Open-label, Multiple Dose, First-in-human Study of CA102N Monotherapy and of CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors (NCT03616574)
Principal Investigator: Dr. Tomislav Dragovich   

Liver Cancer  

REFINE: Regorafenib Observational Study in Hepatocellular Carcinoma (NCT03289273)
Principal Investigator: Dr. Boris Naraev

Neuroendocrine Tumors

An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors (NCT02709889)
Principal Investigator: Dr. Jiaxan Niu 

Pancreatic Cancer 

A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma (NCT02993731)
Principal Investigator: Dr. Madappa Kundranda

A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen (NCT02923921)
Principal Investigator: Dr. Tomislav Dragovich

Phase II Study of PEGPH20 and Pembrolizumab (MK-3475) for Patients With Previously Treated Hyaluronan High (HA-High) Metastatic Pancreatic Ductal Adenocarcinoma (NCT03634332)
Principal Investigator: Dr. Tomislav Dragovich

A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously with or without Gemcitabine as 2nd/3rd line therapy in Advanced Pancreatic Cancer Patients (NCT02650804)
Principal Investigator: Dr. Madappa Kundranda

Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma (NCT03377491)
Principal Investigator: Dr. Tomislav Dragovich

A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy (NCT02184195)
Principal Investigator: Dr. Tomislav Dragovich

Solid Tumor

Phase 1/2 Study of TAS-120 in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations (NCT02052778)
Principal Investigator: Dr. Madappa Kundranda

Genitourinary Cancer (Bladder and Prostate Cancers)

Gynecologic Cancer (Cervical and Ovarian Cancers)

Head and Neck Cancer

Leukemia

Lung Cancer

Lymphoma

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B Cell or T Cell Non-Hodgkin Lymphoma (NHL) (NCT01994382)
Principal Investigator: Dr. Javier Munoz

A Phase I, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects With B-Cell Lymphoid Malignancies (NCT02343120)
Principal Investigator: Dr. Javier Munoz 

An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102) (NCT03039114)
Principal Investigator: Dr. Javier Munoz 

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7) (NCT03391466) 
Principal Investigator: Dr. Javier Munoz

A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006) (NCT03483103)
Principal Investigator: Dr. Javier Munoz (Please note: The study recruitment for this study are currently on hold)

Phase 1 Study of ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T Cell Receptors (CD16V-41BB-CD3ζ), in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma (NCT02776813)
Principal Investigator: Dr. Javier Munoz 

A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL) (NCT03105336)
Principal Investigator: Dr. Javier Munoz

A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma (NCT03677141)
Principal Investigator: Dr. Javier Munoz

An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)(NCT03331198)
Principal Investigator: Dr. Javier Munoz

Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Adv. Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With DLBCL (NCT01897571)
Principal Investigator: Dr. Javier Munoz

A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (ZUMA-12) (NCT03761056)
Principal Investigator: Dr. Javier Munoz

A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies (NCT03598608)
Principal Investigator: Dr. Javier Munoz

Melanoma

Radiation Oncology

Breast Cancer

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NCT1872975)
Principal Investigator: Dr.Emily Grade

Bone Metastases

A randomized trial evaluating rapid delivery of dose escalated hypofractionated radiotherapy for patients diagnosed with bone metastases for effective palliation of
symptoms
 (NCT02163226)
Principal Investigator: Dr.Gary Walker 

Head and Neck Cancer

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Superoxide Dismutase Mimetic GC4419 to Reduce Severe Oral Mucositis (SOM) Associated with Chemoradiotherapy for Locally Advanced, Non-Metastatic Head and Neck Cancer (NCT03689712)
Principal Investigator: Dr.Gary Walker

Prostate Cancer

Prospective Data Registry and Quality of Life Assessment of Men Undergoing High Dose Rate Brachytherapy of the Prostate Using Real-Time Ultrasound Planning 
Principal Investigator: Dr. Anna Likhacheva

Prospective Evaluation of Men Undergoing Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer
Principal Investigator: Dr. Rachit Kumar

Rectal Cancer

A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer (NCT02921256)
Principal Investigator: Dr.Gary Walker

Skin Cancer

Skin Surface Brachytherapy for Non-Melanoma Skin Cancers: Prospective Data Registry and Quality of Life Assessment
Principal Investigator: Dr.Emily Grade

Solid Tumor

EXTernal beam radiation to Eliminate Nominal metastatic Disease (EXTEND): A randomized phase II basket trial assessing the efficacy of upfront local consolidative therapy (LCT) for oligometastatic disease (NCT03599765)
Principal Investigator: Dr.Gary Walker

Solid Tumor